BioRestorative Therapies announces $1.085M registered direct offering

BioRestorative Therapies (BRTX) announced it has entered into definitive agreements with several accredited and/or institutional investors for the sale of 678,125 shares of the company’s common stock at an offering price of $1.60 per share in a registered direct offering. The company’s stock closed at $1.50 per share on October 3, 2025. In a concurrent private placement offering, the company also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 508,594 shares of the company’s common stock, representing 75% warrant coverage. The Unregistered Warrants will have an exercise price of $2.75 per share and will be exercisable commencing six months from the date of issuance until the five year anniversary of the date of issuance. The gross proceeds of the offering will be $1.085M, before deducting placement agent fees and other estimated offering expenses. The closing of the offering is expected to take place on or about October 8, 2025. The company intends to use the net proceeds of the offering in connection with its clinical trials with respect to its lead cell therapy candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem Program, the development of its commercial biocosmeceuticals platform and for general corporate purposes and working capital.